R

P

RUTKOWSKI , P.

Last name: RUTKOWSKI

First name: P.

February 29, 2024 (v1)

Publication

Metadata-only

Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis

Piulats, J. M. Watkins, C. Costa García, M.

Background: Tebentafusp demonstrated a superior overall survival (OS) benefit [hazard ratio (HR) 0.51] compared to investigator's choice (82% pembrolizumab) in a randomized, phase III trial (IMCgp100-202; N ¼ 378) in untreated metastatic uveal melanoma (mUM). The 1-year OS rates for tebentafusp and pembrolizumab were 73% and 59%, respectively....

Uploaded on: March 3, 2024